Format

Send to

Choose Destination
Curr Opin Pharmacol. 2014 Apr;15:22-7. doi: 10.1016/j.coph.2013.11.006. Epub 2013 Nov 27.

HERG1 channel agonists and cardiac arrhythmia.

Author information

1
Department of Internal Medicine, Nora Eccles Harrison Cardiovascular Research & Training Institute, University of Utah, 95 South 2000 East, Salt Lake City, UT 84112, USA. Electronic address: sanguinetti@cvrti.utah.edu.

Abstract

Type 1 human ether-a-go-go-related gene (hERG1) potassium channels are a key determinant of normal repolarization of cardiac action potentials. Loss of function mutations in hERG1 channels cause inherited long QT syndrome and increased risk of cardiac arrhythmia and sudden death. Many common medications that block hERG1 channels as an unintended side effect also increase arrhythmic risk. Routine preclinical screening for hERG1 block led to the discovery of agonists that shorten action potential duration and QT interval. Agonists have the potential to be used as pharmacotherapy for long QT syndrome, but can also be proarrhythmic. Recent studies have elucidated multiple mechanisms of action for these compounds and the structural basis for their binding to the pore domain of the hERG1 channel.

PMID:
24721650
PMCID:
PMC3984452
DOI:
10.1016/j.coph.2013.11.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center